Mineralys Therapeutics
Mineralys Therapeutics develops oral aldosterone synthase inhibitors for hypertension, chronic kidney disease, and obstructive sleep apnea.
424B3Nov 12Latest SEC filing
Nov 4Latest story
November 2026
October 2026
August 2026
Mineralys Therapeutics develops oral aldosterone synthase inhibitors for hypertension, chronic kidney disease, and obstructive sleep apnea.